An interventional study of Stereotactic Body Radiotherapy in Breast Neoplasm Malignant Female, sponsored by King Hussein Cancer Center. Recruiting at 1 site in Jordan. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-11.
Sponsored by King Hussein Cancer Center · Not applicable, Interventional, and Treatment
This is a prospective data collection of treatment outcome for newly diagnosed oligometastatic breast cancers with 1-3 bone metastases. Eligible patients will be identified from the weekly Breast MDC. Patients will receive the recommended systemic and local treatment (including metastases directed SBRT) according to our clinical practice guidelines.Patients will be followed according to our routine with clinical and radiologic assessment. It is preferred that the same imaging method that was used to originally detect the metastases be used in follow-up assessments. The first imaging for SBRT sites will be three months post SBRT and every three months for the first year, every 6 months for the second year, then annually. Response and progression for these metastases will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions is used in the RECIST criteria. If functional imaging (bone scan, PET) were used at staging, changes in the uptake will be used in follow up scans to determine response to treatment and progression. As for SBRT related morbidities, we will use the Common Terminology Criteria for Adverse Events (CTCAE v5) for toxicity reporting and scoring.
Exclusion Criteria:
Newly diagnosed bone only oligometastatic breast cancers with 1-3 bone metastases will be enrolled in this protocol. Patients will receive SBRT to all metastatic sites.
Radiation: Stereotactic Body Radiotherapy
This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
Progression free survival (PFS)
the interval from diagnosis until disease progression
Time frame: 5 years
Overall survival (OS)
time from diagnosis to death from any cause or last follow-up
Time frame: 5 years
Existing metastasis control
the interval from diagnosis until local progression of the treated metastases
Time frame: 3 years
Appearance of new metastases
the interval from diagnosis until appearance of new metastases
Time frame: 3 years
Adverse Events
CTCAE v5. for acute and chronic toxicity reporting and scoring
Time frame: 3 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King Hussein Cancer Center